Comprehensive Therapy

, Volume 33, Issue 2, pp 58–64 | Cite as

Alzheimer’s Disease

Original Article
  • 30 Downloads

Alzheimer’s disease is the most prevalent form of dementia. There are significant efforts underway to elucidate the pathogenesis of this disease and to find ways to lessen the impact of the symptoms. This paper summarizes current knowledge regarding the diagnosis and treatment of the disorder.

References

  1. Hardy J, Selkoe D. The amloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.PubMedCrossRefGoogle Scholar
  2. Riekse R, Leverenz J, McCormick W. Effect of vascular lesions on cognition in Alzheimer’s disease: a community-based study. J Am Geriatr Soc 2004;52:1442–48.PubMedCrossRefGoogle Scholar
  3. Small G, Rabins P, Barry P. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. J Am Med Assoc 1997;278:1363–71.CrossRefGoogle Scholar
  4. Knopman D, DeKosky S, Cummings J. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–53.PubMedGoogle Scholar
  5. Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedCrossRefGoogle Scholar
  6. Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. J Am Med Assoc 1997;277:813–7.CrossRefGoogle Scholar
  7. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–75.CrossRefGoogle Scholar
  8. Lim A, Tsuang D, Kukull W. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999;47:564–9.PubMedGoogle Scholar
  9. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–13.PubMedCrossRefGoogle Scholar
  10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–34.PubMedCrossRefGoogle Scholar
  11. Harvey R, Skelton-Robinson M, Rossor M. The prevalence and causes of dementia in people under age 65 years. J Neurol Neurosurg Psychiatry 2003;74:1206–9.PubMedCrossRefGoogle Scholar
  12. Farrer L, Cupples L, Haines J. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. J Am Med Assoc 1997;278:1349–56.CrossRefGoogle Scholar
  13. Raber J, Huang Y, Ashford J. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641–50.PubMedCrossRefGoogle Scholar
  14. Meyer M, Tschanz J, Norton M. ApoE genotype predicts when-not whether-one is predisposed to develop Alzheimer’s disease. Nat Genet 1998;19:321–2.PubMedCrossRefGoogle Scholar
  15. Tariot P, Solomon P, Morris J. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–76.PubMedGoogle Scholar
  16. Feldman H, Gauthier S, Hecker J. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–20.PubMedGoogle Scholar
  17. Rosler M, Retz W, Retz-Junginger P. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer’ disease. Behav Neurol 1998;11:211–6.PubMedGoogle Scholar
  18. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer’s disease. Am J Psychiatr 1984;141:1356–64.PubMedGoogle Scholar
  19. Francis P, Palmer A, Snape M. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47.PubMedCrossRefGoogle Scholar
  20. Cummings J. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131–45.PubMedCrossRefGoogle Scholar
  21. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD005593.Google Scholar
  22. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 2004;363:2105–15.CrossRefGoogle Scholar
  23. Bullock R, Touchon J, Bergman H. Rivastigimine and donezepil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21:1317–27.PubMedCrossRefGoogle Scholar
  24. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59:817–22.PubMedCrossRefGoogle Scholar
  25. Geldmacher D, Provenzano G, McRae T. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2003;51:937–44.PubMedCrossRefGoogle Scholar
  26. Sano M, Wilcock G, Van Baelen B. The effects of galantamine treatment on caregiver time in Alzheimer’s disease. Int J Geriatr Psychiatry 2003;18:942–50.PubMedCrossRefGoogle Scholar
  27. Galasko D, Kershaw P, Schneider L. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease. J Am Geriatr Soc 2004;52:1070–6.PubMedCrossRefGoogle Scholar
  28. Mohs R, Doody R, Morris J. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481–8.PubMedGoogle Scholar
  29. Potkin S, Anand R, Hartman R. Impact of Alzheimer’s disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuro-Psychopharmacol Biol Psychiatry 2002;26:713–20.CrossRefGoogle Scholar
  30. Doody R, Stevens J, Beck C. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–66.PubMedGoogle Scholar
  31. Reisberg B, Doody R, Stoffler A. Memantine in moderate-to-severe Alzheimers disease. N Engl J Med 2003;348:1333–41.PubMedCrossRefGoogle Scholar
  32. Areosa S, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005;3:CD003154.Google Scholar
  33. Tariot P, Farlow M, Grossberg G. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 2004;291:317–24.CrossRefGoogle Scholar
  34. Morris M, Beckett L, Pa S. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:121–6.PubMedCrossRefGoogle Scholar
  35. Sano M, Ernesto C, Thomas R. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997;336:1216–22.PubMedCrossRefGoogle Scholar
  36. Petersen R, Thomas R, Grundman M. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–88.PubMedCrossRefGoogle Scholar
  37. Wolozin B, Brown Jr, Theisler C. The cellular biochemistry of cholesterol and statins: insights in the pathophysiology and therapy of Alzheimer’s disease. CNS Drug Rev 2004;10:127–46.PubMedCrossRefGoogle Scholar
  38. Rea T, Breitner J, Psaty B. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047–51.PubMedCrossRefGoogle Scholar
  39. Zandi P, Sparks D, Khachaturian A. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217–24.PubMedCrossRefGoogle Scholar
  40. Mulnard R, Cotman C, Kawas C. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. J Am Med Assoc 2000;283:1007–15.CrossRefGoogle Scholar
  41. Shumaker S, Legault C, Kuller L. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women: Women’s Health Initiative Memory Study. J Am Med Assoc 2004;291:2947–58.CrossRefGoogle Scholar
  42. Kanowski S, Hoerr R. Ginko biloba extract Egb 761 dementia: intent-to-treat analyses of a 24 week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297–303.PubMedCrossRefGoogle Scholar
  43. Aisen P, Schafer K, Grundman M. Alzheimer’s Disease Cooperative Study: effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 2003;289:2819–26.CrossRefGoogle Scholar
  44. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16:599–606.PubMedCrossRefGoogle Scholar
  45. Orgogozo J, Gilman S, Dartigues J. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46–54.PubMedGoogle Scholar
  46. Geerts H. NC-531 (Neurochem). Curr Opin Investig Drugs 2004;5:95–100.PubMedGoogle Scholar
  47. Cherny R, Atwood C, Xilinas M. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001;30:665–76.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society of Contempary Medicine and Surgery 2007

Authors and Affiliations

  1. 1.Department of Psychiatry and Human BehaviorThe Warren Alpert Medical School of Brown UniversityProvidenceUSA
  2. 2.Departments of PsychiatryRhode Island Hospital and The Miriam HospitalProvidenceUSA

Personalised recommendations